Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Increases Stake in Calando

Premium

Arrowhead Research said this week that it has increased its majority ownership in RNAi drugs developer Calando Pharmaceuticals.

Arrowhead said it exchanged a warrant to purchase approximately 3.9 million shares of its stock for Calando Series A preferred stock with a liquidation preference of approximately $3.9 million.

"The Calando preferred stock is convertible into 2.7 million shares of Calando common stock at the discretion of the holder," Arrowhead said.

The warrants have an exercise price of $0.50 per share and are exercisable beginning March 17, 2011. They expire Sept. 16, 2015.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.